Licensable Patents as the Background Information in Mobility
Patent on microfluidic sensor (TRL3) that will be converted into OA sensing and we want to go to TRL6 and beyond with industry support.
Patent on SPR sensors (TRL3) that will be converted into OA sensing and we want to go to TRL6 and beyond with industry support.
Patent on new therapeutic- nucleic acids (TRL3) that will be converted into articular treatment and we want to go to TRL6 and beyond with industry support.
Patent on micro-needles (TRL3) that we want to go to TRL6 and beyond with industry support.
Patent on peptides for use as senotherapeutic agents. (María D. Mayán; Marta Varela-Eirín; Alejandro Castro-Iglesias; Eugenio Vázquez-Sentís; José L. Mascareñas; Soraya Learte-Aymamí; José R. Caeiro; Elena Pazos. PCT/EP2020/071242_06/04/2021. UVigo).
Patent on the compositions and methods to treat inflammatory joint diseases. (Mayan M.D.; Blanco F.J.; Carpintero-Fernandez P.; Goldberg G.S.PCT/US2014/045229_United States of America. 02/07/20).
Public-Private Partnership
Innovative Health Initiative (IHI)(https://www.ihi.europa.eu/ ) is an EU public-private partnership funding health research and innovation. By leveraging the skills of a range of scientific fields – from pharmaceuticals and biotechnology to medical technology and big data – we fund projects that will address public health needs, improve patients’ lives, and boost the competitiveness of Europe’s health industries. The Innovative Health Initiative Joint Undertaking (IHI JU) is a partnership between the European Union and industry associations representing the sectors involved in healthcare, namely COCIR (medical imaging, radiotherapy, health ICT and electromedical industries); EFPIA, including Vaccines Europe (pharmaceutical industry and vaccine industry); EuropaBio (biotechnology industry); and MedTech Europe (medical technology industry).
IHI Call 9 is a single stage call (https://www.ihi.europa.eu/apply-funding/future-opportunities ) with five topics aligned with the five specific objectives set out in the IHI Strategic Research and Innovation Agenda (SRIA) (https://www.ihi.europa.eu/sites/default/files/flmngr/IHI_Strategic_Research_and_Innovation_Agenda_3.pdf ). These topics are:
HORIZON-JU-IHI-2025-09-01
Boosting innovation for a better understanding of the determinants of health.
HORIZON-JU-IHI-2025-09-02
Boosting innovation through better integration of fragmented health R&I efforts.
HORIZON-JU-IHI-2025-09-03
Boosting innovation for peopled centred integrated healthcare solutions.
HORIZON-JU-IHI-2025-09-04
Boosting innovation through exploitation of digitalisation and data exchange in healthcare.
HORIZON-JU-IHI-2025-09-05
Boosting innovation for better assessment of the added value of innovative integrated healthcare solutions.
In line with this information, we are willing to collaborate with COCIR, EFPIA, Med Tech Europe and EuropaBio Industry partners to ensure 50% of the action’s eligible costs. Private members which are members of IHI JU, their constituent or affiliated entities, and contributing partners will be invited for in-kind contribution to our project proposal.
Our consortium has focused on preparing our project proposal to topic 5, HORIZON-JU-IHI-2025-09-05. Boosting innovation for better assessment of the added value of innovative integrated healthcare solutions. We are willing to generate new tools for the diagnosis and treatment of osteoarthritis (OA). Artificial intelligence marker less based motion analysis technology (Patent #12089755) can facilitate the early diagnosis of OA in large populations. Multi-omics outcomes from the serum and synovial joint fluid may determine the natural course of OA. Specific markers can be transferred to the production of OA specific biosensors. We have two biosensor patents (Patent #TR2014_14481B and Patent TBD) that will be converted into OA specific biosensors in the scope of this project proposal. We also have a patent for the peptide delivery system that was generated with the EU H2020 grant 874790. The knowledge will be transferred to OA treatment in this project. We also have a patent for the microneedles technology that can be used for the delivery of new therapeutics into the subcutaneous blood circulation. We further have two other patents on peptides for use as senotherapeutic agents and on the compositions and methods to treat inflammatory joint diseases. Our aim is to take these patents from their TRL3 to TRL6 by planning clinical trials.